HOTH - Hoth Therapeutics shares rise on positive data from anti-cancer therapeutic

Hoth Therapeutics (HOTH) shares surge more than 17% during premarket trading after the company announces that its novel anti-cancer therapeutic exhibited positive results in humanized mast cell neoplasm models, representative in vitro and in vivo models for aggressive, mast cell-derived cancers such as mast cell leukemia and mast cell sarcoma.The anti-cancer therapeutic, which is currently in development, uses mRNA frame shifting that induces apoptosis of neoplastic mast cells.These findings show that the novel anti-cancer therapeutic rapidly induces apoptosis and cell death in neoplastic mast cells, the company said. There were no obvious signs of toxicity in the study animals, suggesting that the novel anti-cancer therapeutic was well-tolerated.Hoth plans to pursue rapid development of the potential therapeutic to support initiation of clinical trials.

For further details see:

Hoth Therapeutics shares rise on positive data from anti-cancer therapeutic